Page last updated: 2024-09-03

lysyl-aspartyl-glutamyl-leucine and Breast Cancer

lysyl-aspartyl-glutamyl-leucine has been researched along with Breast Cancer in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Batra, SK; Bigner, DD; Lorimer, IA; Pastan, I; Wikstrand, CJ1
Abad, JL; Bernad, A; Gómez-Moutón, C; González, MA; Lacalle, RA; Mañes, S; Martínez-A, C; Mira, E1

Other Studies

2 other study(ies) available for lysyl-aspartyl-glutamyl-leucine and Breast Cancer

ArticleYear
Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:8

    Topics: 3T3 Cells; Animals; Antibodies, Monoclonal; Breast Neoplasms; Cell Survival; Drug Design; ErbB Receptors; Female; Glioma; Humans; Immunotoxins; Lung Neoplasms; Mice; Mutagenesis, Site-Directed; Oligopeptides; Protein Sorting Signals; Recombinant Proteins; Sequence Deletion; Transfection

1995
A role for chemokine receptor transactivation in growth factor signaling.
    EMBO reports, 2001, Volume: 2, Issue:2

    Topics: Breast Neoplasms; Cell Polarity; Chemokine CCL5; Chemotaxis; GTP-Binding Protein alpha Subunits, Gi-Go; Humans; Insulin-Like Growth Factor I; Ligands; Mutation; Neoplasm Invasiveness; Oligopeptides; Phosphorylation; Protein Sorting Signals; Receptors, CCR5; RNA, Messenger; Signal Transduction; Transcriptional Activation; Tumor Cells, Cultured

2001